Daiichi Sankyo announced today that its antibody-drug conjugate (ADC) Datroway (datopotamab deruxtecan), developed in collaboration with AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative unresectable or recurrent breast cancer who have received chemotherapy. This is the first approval of this therapy globally. It is worth mentioning that this ADC has been listed by the industry media Evaluate as one of the top ten potential blockbuster R&D projects of 2024. (WUXI APPTEC WeChat official account)
全球首批！潜在重磅ADC获批治疗乳腺癌
The world's first batch! A potential blockbuster ADC has been approved for the treatment of breast cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.